Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Legend Bio Plans to Raise $250 Million in Public Offering of Shares

publication date: Jul 26, 2022

Legend Biotech, a New Jersey-Nanjing cell therapy company, announced plans to raise $250 million by selling American Depositary Shares in an underwritten public offering. In February, Legend was approved to launch its BCMA CAR-T therapy, Carvykti, as a fitth-line therapy for multiple myeloma in the US, and EU approval followed in May. At the recent ASCO convention, Legend revealed the CAR-T had not reached a median progression of disease or death after more than two years in MM patients. Legend is conducting tests of Carvykti as a second-line therapy for MM. More details....

Stock Symbol: (NSDQ: LEGN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022